Inactive Instrument

Ablynx Share Price

Equities

ABLX

BE0003877942

Biotechnology & Medical Research

Chart Ablynx

Duration

Period

Style

Latest news about Ablynx

AstraZeneca : Novo Nordisk hires AstraZeneca executive to revive struggling biopharma unit	15/18/15	RE
Sanofi : sees new acquisitions and drugs reviving growth	27/18/27	RE
Blackstone LP : Sanofi in talks to sell generics arm to Advent for 1.9 billion euros	17/18/17	RE
Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide	29/18/29	RE
Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide	29/18/29	RE
Takeda Pharmaceutical : Drugmaker Shire soars as Japan's Takeda considers bid	29/18/29	RE
Ablynx : Drugmaker Novo Nordisk looks to former oil boss to energise M&A	22/18/22	RE
Ablynx : Sanofi's return to profit growth this year slower than hoped	07/18/07	RE
Ablynx : Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom	30/18/30	RE
Ablynx : Chipmakers, Sanofi deal dominate European share trading	29/18/29	RE
Ablynx : Novo Nordisk remains on hunt for biopharma deals	29/18/29	RE
Ablynx : Biotech M&A takes off as Sanofi and Celgene spend $20 billion	22/18/22	RE
Biogen : Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion	22/18/22	RE
Bioverativ : New drugs recast $10 billion haemophilia market as Sanofi swoops in	22/18/22	RE
Associated British Foods : European shares edge higher as cyclicals back in favour	18/18/18	RE

Analyst Recommendations on Ablynx

Associated British Foods : European shares edge higher as cyclicals back in favour	18/18/18	RE
Ablynx : Bond sell-off hits European shares but boost banks	10/18/10	RE

More recommendations

Press releases Ablynx

Immunicum : and DCprime Combine Forces to Establish Leader in Cell-Based Cancer Immunotherapies	19/20/19	AQ
Ablynx : SANOFI COMPLETES ITS ACQUITISION OF ABLYNX FOLLOWING THE EXPIRATION OF THE SQUEEZE-OUT PROCEDURE	19/18/19	GL
Ablynx : PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")	28/18/28	GL
Ablynx : PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")	28/18/28	GL
Ablynx : NOTICE IN RELATION TO THE CONVERTIBLE BONDS DUE MAY 2020	25/18/25	GL

More press releases

News in other languages on Ablynx

SANOFI : a finalisé l'acquisition d'Ablynx	19/18/19
Les marchés européens marquent une pause, scrutent la politique italienne	14/18/14
Sanofi : A suivre aujourd'hui	14/18/14
SANOFI : détient 95,60% des actions d'ABLYNX	14/18/14
Sanofi : L'offre publique d'achat de Sanofi sur Ablynx débutera le 4 avril	29/18/29

Managers and Directors - Ablynx

Managers	Title	Age	Since
Petrus Houwen CEO	Chief Executive Officer	-	01/19/01

Members of the board	Title	Age	Since
Kristine de Sutter BRD	Director/Board Member	-	01/19/01
Pieter Oldenziel BRD	Director/Board Member	-	01/19/01

Company Profile

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer